Stock Exchanging Hands at a Rapid Volume Today: Nektar Therapeutics (NASDAQ:NKTR)

Postado Novembro 14, 2017

The stock has been active on the tape, now trading at $32.50, up from yesterday's close by 2.39%. The Company's divisions include Microcontroller and Connectivity Division, and Memory Products Division (MPD). MCD focuses on microcontroller (MCU), analog and wireless and wired connectivity solutions.

On November 8 Mizuho held the stock rating at "Buy" with a current price target of $30.00. Therefore 100% are positive. Nektar Therapeutics has a 12-month low of $10.52 and a 12-month high of $19.98. The stock presently has a consensus rating of "Buy" and an average target price of $31.82.

Nektar Therapeutics on 9/29/2017 reported its EPS as $-0.28 with the analysts projecting the EPS of the stock as $-0.26. The stock has "Buy" rating by Oppenheimer on Thursday, August 3.

Shares of Nektar Therapeutics (NASDAQ:NKTR) have been recently spotted trading 11.63% off of the 52-week high price. William Blair reissued an outperform rating on shares of Nektar Therapeutics in a report on Tuesday, July 18th. They expect $-0.34 EPS, down 21.43% or $0.06 from last year's $-0.28 per share. During the same period in the prior year, the company posted ($0.32) EPS. Finally, Brean Capital reissued a "buy" rating and set a $23.00 price objective on shares of Nektar Therapeutics in a research note on Friday, September 30th.

When investing in a volatile security, the risk of success is increased just as much as the risk of failure. Its up 0.72, from 1.17 in 2017Q1. On Monday, May 15 CHESS ROBERT sold $98,950 worth of Nektar Therapeutics (NASDAQ:NKTR) or 5,000 shares. 25 funds opened positions while 83 raised stakes. 2,356 were accumulated by Royal Comml Bank Of Canada. Parametric Port Assoc Lc invested in 0.01% or 325,501 shares. Teachers Retirement Systems Of The State Of Kentucky owns 47,000 shares.

About 9.14M shares traded or 501.32% up from the average. Highland Cap Mgmt L P holds 25,000 shares. Da Davidson & owns 75,685 shares for 0.01% of their portfolio. Bragg Financial Advisors Inc, a North Carolina-based fund reported 54,428 shares. The mean target price as estimated by the analysts for the company has been recorded at $15.46. Pinebridge Limited Partnership holds 0.05% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 93,694 shares. Bridger Mngmt Lc holds 2.81M shares or 3.14% of its portfolio. Ameriprise Incorporated reported 952,443 shares. NJ State Employees Deferred Compensation Plan's holdings in Nektar Therapeutics were worth $480,000 at the end of the most recent reporting period. 1,450 shares were sold by Gergel Ivan P., worth $28,348. The shares were sold at an average price of $24.97, for a total transaction of $1,090,614.69. ROBIN HOWARD W sold $163,985 worth of stock. Shares for $33,255 were sold by Doberstein Stephen K. The insider Labrucherie Gil M sold $62,149. Roth Capital maintained it with "Buy" rating and $32.5 target in Wednesday, August 30 report.

Nektar Therapeutics is a biopharmaceutical firm that discovers and develops medicines in areas of high unmet medical need. The most current P/E ratio is N/A and the market value is 5.84B. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are created to enable the development of new molecular entities that target known mechanisms of action.

Robertson Opportunity Capital Llc holds 3.21% of its portfolio in Cypress Semiconductor Corporation for 370,000 shares. Moreover, Lapides Asset Management Llc has 0.68% invested in the company for 66,900 shares.

The National Harbor, Maryland-based Nektar announced the first presentation of data from the PIVOT-02 Phase 1/2 Study, which is created to evaluate the combination of Bristol-Myers Squibb's Opdivo (nivolumab) with Nektar's investigational medicine, NKTR-214. (:RELY). The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of 2.50.

Analysts await Irsa Inversiones y Rprsntcins SA (ADR) (NYSE:IRS) to report earnings on December, 5.

Since January 1, 0001, it had 0 buys, and 1 insider sale for $89,464 activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.